drugset / Trial / NCT06088030
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.
Timeline
- Start
- 2023-12-13
- Primary completion
- 2031-12-14
- Completion
- 2031-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | arsenic trioxide | Small molecule | 0.18 mg/kg | Intravenous |